Table 1.
Demographic and clinical characteristics of included studies.
| Source | Sample(F) | Age(years) | Duration(years) | Trial Duration | Agent (Daily Dosage) | Comparator (Dosage) |
|---|---|---|---|---|---|---|
| Aso Y (19) | 57 (23) | 55.0 ± 8.6 | NR | 24 weeks | Standard-hypoglycemic treatment | Standard-hypoglycemic treatment |
| + dapagliflozin 5 mg | ||||||
| Bando Y (18) | 62 (22) | 55.1 ± 8.6 | 9.6 ± 4.5 | 12 weeks | Continued-hypoglycemic treatment | Continued-hypoglycemic treatment |
| + ipragliflozin 50 mg | ||||||
| Eriksson JW (17) | 42 (9) | 65 ± 36 | 6.6 ± 5.1 | 12 weeks | Dapagliflozin 10 mg | Placebo |
| Han E (11) | 45 (17) | 53.9 ± 10.9 | 9.4 ± 5.8 | 24 weeks | Metformin + pioglitazone | Metformin + pioglitazone |
| + ipragliflozin 50 mg | ||||||
| Ito D (16) | 66 (34) | 58.2 ± 10.9 | 9.1 ± 5.8 | 24 weeks | Ipragliflozin 50 mg | Pioglitazone 15-30 mg/day |
| Johansson L (15) | 82 (41) | 58.0 ± 9.0 | 6.4 ± 6.0 | 52 weeks | metformin + saxagliptin 5 mg + placebo + dapagliflozin 10mg | metformin + glimepiride 1-6 mg + placebo |
| Kinoshita T (10) | 98 (45) | 59 ± 1 | 7.2 ± 0.5 | 28 weeks | Dapagliflozin 5 mg | Pioglitazone 7.5–15 mg/day |
| Kuchay MS (14) | 50 (20) | 65.3 ± 6.23 | NR | 20 weeks | Standard-hypoglycemic treatment | Standard-hypoglycemic treatment |
| + empagliflozin 10 mg | ||||||
| Mittag-Roussou V (13) | 39 (19) | 57.7 ± 10.9 | NR | 6 months | Dapagliflozin 5 – 10 mg empagliflozin 10 – 25 mg | Exenatide 10 – 20 μg or liraglutide 0.6 - 1.8 mg or dulaglutide 0.75 - 1.5 mg/week. |
| Shibuya T (12) | 32 (14) | 56.5 ± 11.68 | 9.6 ± 1.0 | 6 months | Luseogliflozin 5 mg | Metformin 1500 mg/day |
F, Female; NR, No report.